Aurora Cannabis Announces Full Year and Fiscal 2026 Fourth Quarter Results with Record Annual Revenue and Adjusted EBITDA¹
Aurora Cannabis reported record fiscal 2026 annual revenue of $320.6 million and Adjusted EBITDA of $53.8 million, driven by 18% growth in global medical cannabis sales. However, Q4 results showed significant weakness with Adjusted EBITDA falling 34% year-over-year to $9.2 million and free cash flow dropping 94% to $0.3 million, pressured by higher SG&A and margin compression. The company completed the $26.5 million acquisition of Safari Flower Company to expand EU-GMP capacity, while exiting its low-margin consumer business and divesting its stake in Bevo Agtech.
Key figures
- Eps
- 0
- Eps Beat
- 0
- Revenue
- 320593000
- Guidance
- FY27 Total Net Revenue expected to decline; Adjusted Gross Margin mid-to-high 50s%; Adjusted EBITDA expected to be lower than prior fiscal year
- Revenue Yoy
- 11%
- Deal Value Usd
- 26500000
- Offering Price
- 0
- Shares Offered
- 0
- Q4 revenue
- 84816000
- Q4 revenue yoy
- 10%
- Q4 free cash flow
- 316000
- Q4 adjusted ebitda
- 9227000
- Medical revenue yoy
- 18%
- Cash and equivalents
- 164700000
- Q4 free cash flow yoy
- -94%
- Annual adjusted ebitda
- 53808000
- Medical revenue annual
- 288640000
- Q4 adjusted ebitda yoy
- -34%
- Annual adjusted ebitda yoy
- 32%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.